We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
- Authors
Sievers, E L; Larson, R A; Stadtmauer, E A; Estey, E; Löwenberg, B; Dombret, H; Karanes, C; Theobald, M; Bennett, J M; Sherman, M L; Berger, M S; Eten, C B; Loken, M R; van Dongen, J J; Bernstein, I D; Appelbaum, F R; Mylotarg Study Group
- Abstract
Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an antibody-targeted chemotherapy agent, in patients with CD33-positive acute myeloid leukemia (AML) in untreated first relapse.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 13, p3244
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.13.3244